Interleukin-4 treatment for chronic pityriasis lichenoides
Part of Skin clinical trials.
This study tests a new treatment called interleukin-4 for pityriasis lichenoides chronica (a chronic skin condition with scaly bumps or patches). It may help reduce symptoms and improve the skin's appearance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pityriasis lichenoides chronica (PLC), confirmed by a skin biopsy.
- You are 8 years old or older.
- You do not have any other skin disease.
- You haven't had treatment for PLC within the last 3 months.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with lichen planus (a rash that can affect skin, mouth, or genitals) to find markers in cells and blood that may help understand the disease. If you have a new diagnosis or a flare-up, and you are not on strong immune-suppressing medicine, you may be able to join.
This trial tests a new drug that targets a protein called IRAK4, which is involved in the growth of cancer cells in chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can help people with CLL.
This study looks at the immune cells in skin samples from people with psoriasis who are being treated with an anti-IL-23 biologic. The goal is to understand why some areas of skin do not improve or why flares happen, which may help improve treatments.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This study tests a new medication for people with moderate to severe lichen planus that has not improved with topical treatments. The goal is to see if it reduces symptoms and improves quality of life.
This trial tests a new medicine called Bimekizumab (Bimzelx) to see if it improves PRP, a rare skin condition that causes red, scaly patches. If you have moderate to severe PRP, this treatment might help clear your skin.
Hear when a new Pityriasis Lichenoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.